


2019-01-01

Platelet Biology And Thrombosis: Juul E-Cigarette Exposure And 5ht2a Receptor Drug Discovery

Jean Emmanuel Montes Ramirez
University of Texas at El Paso

Follow this and additional works at: https://digitalcommons.utep.edu/open_etd

 Part of the [Biology Commons](#), [Biomedical Commons](#), and the [Pharmacy and Pharmaceutical Sciences Commons](#)

Recommended Citation

Montes Ramirez, Jean Emmanuel, "Platelet Biology And Thrombosis: Juul E-Cigarette Exposure And 5ht2a Receptor Drug Discovery" (2019). *Open Access Theses & Dissertations*. 2879.
https://digitalcommons.utep.edu/open_etd/2879

This is brought to you for free and open access by ScholarWorks@UTEP. It has been accepted for inclusion in Open Access Theses & Dissertations by an authorized administrator of ScholarWorks@UTEP. For more information, please contact lweber@utep.edu.

PLATELET BIOLOGY AND THROMBOSIS: JUUL E-CIGARETTE
EXPOSURE AND 5HT_{2A} RECEPTOR DRUG DISCOVERY

JEAN EMMANUEL MONTES RAMIREZ

Master's Program in Biomedical Engineering

APPROVED:

Fatima Z. Alshbool, PharmD, Ph.D., Chair

Fadi T. Khasawneh, Ph.D.

Zubair A. Karim, Ph.D.

Thomas Boland, Ph.D.

Stephen L Crites, Jr., Ph.D.
Dean of the Graduate School

Copyright ©

by

Jean Emmanuel Montes Ramirez

2019

Dedication

For my loving family who has always been there for me. You have been an immense motivator to me. My hardworking father who has always provided me with opportunities and guided me along the way. My diligent mother has always taken care of me and who taught me respect, honesty, compassion, and perseverance. My brothers who have always been by my side guiding and helping me. I dedicate this work to everyone who has been with me in this endeavor.

PLATELET BIOLOGY AND THROMBOSIS: JUUL E-CIGARETTE
EXPOSURE AND 5HT_{2A} RECEPTOR DRUG DISCOVERY

by

JEAN EMMANUEL MONTES RAMIREZ, B.S.

THESIS

Presented to the Faculty of the Graduate School of

The University of Texas at El Paso

in Partial Fulfillment

of the Requirements

for the Degree of

MASTER OF SCIENCE

Department of Metallurgical, Materials, and Biomedical Engineering

THE UNIVERSITY OF TEXAS AT EL PASO

December 2019

Acknowledgements

I want to express my sincere gratitude to my advisor Dr. Fatima Alshbool for providing me the opportunity to work, study, learn and conduct research under her guidance. Her continuous support, motivation, patience, and vast knowledge helped me reach this achievement. Dr. Fadi Khasawneh for always been supportive and allotting time to teach me and guide me. Dr. Zubair Karim for having the patience to teach me the lab techniques, as well as for encouraging and guiding me. Dr. Boland, for granting me the opportunity to advance my education and conduct research at UTEP. Graduate student Ahmed Alarabi, for the interesting discussions we had while performing aggregation till late, and whom also provided me assistance and good insight. A very special thanks to everyone in the laboratory Keziah Hernandez, Patricia Lozano, Victor Rodriguez. I also would like to thank all the faculty and staff from the Metallurgical, Materials and Biomedical engineering, School of Pharmacy, Laboratory Animal Resources Center, human donor participants, and the funding agencies (Startup funds, the American Heart Association, and the NIH; the National Institute of Environmental Health Sciences and the National Heart, Lung, And Blood Institute, of the National Institutes of Health under Awards Number R21ES029345 and R01HL145053).

Table of Contents

Acknowledgements	v
Table of Contents	vi
List of Figures.....	x
Chapter I: Platelet Biology and E-Cigarettes	1
Section 1.1. Platelet physiology and function	1
Section 1.1.1. Platelet clot formation	1
Section 1.1.2. Transmembrane receptors	3
Section 1.1.3. G-protein coupled receptors signaling	3
Section 1.2. E-cigarettes	4
Section 1.2.1. E-cigarette JUUL	5
Section 1.3. Serotonin	6
Chapter II: : JUUL E-Cigarette Increases the Risk of Thrombosis and Enhances Platelet Function in Mice.	8
Section 2.1. Abstract	8
Section 2.2. Introduction	9
Section 2.3. Materials and Methods	11
Section 2.3.1. Materials and Reagents	11
Section 2.3.2. Animals	11
Section 2.3.3. JUUL e-cigarette exposure protocol	12
Section 2.3.4. Methods	12
Section 2.3.5. Cotinine Assay	13
Section 2.3.6. In vivo thrombosis model.....	13

Section 2.3.7. Tail bleeding Time assay.....	13
Section 2.3.8. Murine Platelet-Rich Plasma Preparation	14
Section 2.3.9. Washed platelet preparation	14
Section 2.3.10. In vitro platelet aggregation	14
Section 2.3.11. Flow cytometric analysis	15
Section 2.3.12. Immunoblotting.....	15
Section 2.3.13. Statistical analysis	16
Section 2.4. Results	17
Section 2.4.1. JUUL E-Cigarette Exposure Systematically Delivers Nicotine	17
Section 2.4.2. JUUL E-Cigarette Exposed Mice Exhibit Enhanced Physiological Hemostasis and Thrombus Formation	18
Section 2.4.3. JUUL E-Cigarette Exposure Enhances ADP-, and Thrombin- Induced Platelet Aggregation	19
Section 2.4.4. JUUL E-Cigarette Exposure Enhances ADP-, and Thrombin- Induced Platelet Secretion	20
Section 2.4.5. JUUL E-Cigarette Exposure Enhances ADP-, and Thrombin- Induced Integrin GPIIb/IIIa Activation and Phosphatidylserine Exposure	21
Section 2.4.6. JUUL E-Cigarette Exposure Enhances Akt and ERK Activation	22
Section 2.5. Discussion	24
Section 2.6. Conclusion.....	27
CHAPTER III: A Novel Antibody Targeting The Second Extracellular Loop of The Serotonin 5-HT _{2A} Receptor Inhibits Platelet Function.	28
Section 3.1. Abstract	28
Section 3.2. Introduction	29

Section 3.3. Materials and Methods	31
Section 3.3.1. Materials and Reagents	31
Section 3.3.2. Animals	31
Section 3.3.3. Human and Murine Platelet Preparation	32
Section 3.3.4. In vitro Platelet Aggregation	32
Section 3.3.5. Ex vivo Platelet Aggregation	33
Section 3.3.6. Flow cytometric analysis	33
Section 3.3.7. In vivo thrombosis model.....	34
Section 3.3.8. Tail bleeding Time assay.....	34
Section 3.3.9. Radioligand Binding Displacement.....	35
Section 3.3.10. Statistical analysis.....	35
Section 3.4. Results	36
Section 3.4.1. 5HT _{2A} RAb Inhibits Serotonin-enhanced Human Platelet Aggregation.....	36
Section 3.4.2. 5HT _{2A} RAb Inhibits Serotonin-enhanced Mouse Platelet Aggregation ex vivo.....	38
Section 3.4.3. 5HT _{2A} RAb inhibits Serotonin-enhanced ADP-induced Platelet Dense Granule Secretion in Human and Mouse Platelets ex vivo.	39
Section 3.4.4. 5HT _{2A} RAb Inhibits Serotonin-enhanced Platelet α Granule Secretion, Glycoprotein IIb/IIIa Activation and Phosphatidylserine Exposure.....	40
Section 3.4.5. 5HT _{2A} RAb Prolongs the Thrombus Occlusion Time but not the Tail Bleeding Time	42
Section 3.4.6. 5HT _{2A} RAb Displaces the 5HT _{2A} R Antagonist Ketanserin from its Binding Sites.....	43
Section 3.5. Discussion	45

Section 3.6. Conclusion.....	47
References.....	49
Vita.....	57

List of Figures

Figure 1.1. Platelet clot formation	2
Figure 2.1. JUUL exposure results in systemic delivery of nicotine (cotinine).	17
Figure 2.2 JUUL exposure shortens the tail bleeding and occlusion times.....	18
Figure 2.3. Platelet aggregation is enhanced in JUUL exposed mice.	19
Figure 2.4. Platelet dense and α granule secretion are enhanced in JUUL exposed mice.....	20
Figure 2.5. Integrin GPIIb/IIIa activation and phosphatidylserine (PS) exposure are increased in JUUL exposed mice.....	22
Figure 2.6. Platelet Akt (protein kinase B) and ERK (extracellular signal-regulated kinases) activation (phosphorylation) is enhanced in JUUL exposed mice.....	23
Figure 3.1. The 5HT _{2A} RAb inhibits serotonin-enhanced ADP-induced human platelet aggregation in vitro.....	37
Figure 3.2. The 5HT _{2A} RAb inhibits serotonin-enhanced ADP-induced mouse platelet aggregation ex vivo.	38
Figure 3.3. The 5HT _{2A} RAb inhibits serotonin-enhanced ADP-induced secretion in human and mouse platelets ex vivo.	40
Figure 3.4. The 5HT _{2A} RAb Inhibits serotonin-enhanced ADP-induced α granule secretion, GPIIb/IIIa activation and PS Exposure, in human platelets in vitro.	41
Figure 3.5. 5HT _{2A} RAb prolongs the time to occlusion but not the tail bleeding time, in mice.....	43
Figure 3.6. 5HT _{2A} RAb displaces the 5HT _{2A} R antagonist from its binding sites.....	44

CHAPTER I: Platelet biology and E-Cigarette

Section 1.1. Platelet physiology and function

Cardiovascular disease annually accounts for 17 million deaths worldwide. It is the number one cause of death in the world (1). According to the American Heart Association, annually, one in every three deaths are caused from a heart disease, stroke and other cardiovascular diseases in the United States alone (2). Cardiovascular disease is tightly linked to platelets, as platelets play an important role in the development of thrombosis, which is a form of and a risk factor for other types of cardiovascular diseases (3).

Platelets are tiny disk-shaped anucleate cell fragments that are created in the bone marrow from megakaryocytes (4-6). Platelets primarily function as regulators of hemostasis and thrombosis (7). Hemostasis is the spontaneous arrest of blood loss from an injured blood vessel (3, 6). In contrast, thrombosis is the pathological process in which an occlusive thrombus forms and blocks blood flow to vital organs (i.e. inappropriate formation of clots) (3).

Section 1.1.1. Platelet clot formation

When injury to the blood vessel wall occurs, two adhesion receptors are responsible for regulating initial platelet adhesion, namely glycoprotein Ib-IX-V which binds to von Willebrand factor, and glycoprotein VI which binds to collagen (8-13). Subsequently, rapid signal transduction causes platelets to activate. During this activation; spreading and secretion occur while platelets also undergo a cytoskeletal change, thus, changing shape (7). In addition, aggregation and adhesion is supported by inside-out activation of integrins. The main platelet integrin that is activated during platelet aggregation is $\alpha\text{IIb}\beta\text{3}$

(also known as GPIIb/IIIa), which binds to fibrinogen to mediate platelet aggregation (12, 14, 15). Furthermore, when platelet activation occurs, platelet secretion is initiated ultimately resulting in the release of different platelet agonists, such as, adenosine diphosphate (ADP) from the platelets storage granules, as well as the synthesis of the lipid thromboxane A₂ (TXA₂). These agonists will lead to activation of further platelets and their recruitment, until a plug made of platelet aggregates finally forms at the injury site (4, 7, 16). In addition, platelets are involved in the conversion of the clotting factor prothrombin to thrombin. Thrombin will convert fibrinogen to fibrin. Fibrin will create a mesh in and around the injury site, thus, completing the hemostatic process (4).




Figure 1.1. (A) Schematic representation of platelet clot formation. (B) Platelet role in hemostasis and thrombosis (17).

Section 1.1.2. Transmembrane receptors

Agonists receptors that belong to this family are expressed on the surface of the platelets. These agonists include ADP and thrombin receptors which play an important role in platelet aggregation and secretion. ADP is a weak agonist that is found in dense granules, and is secreted from platelets upon activation (16). ADP receptors are separated into two different G-Protein coupled receptors (GPCR), those being P2Y₁ and P2Y₁₂; both of which engage a different signaling pathway, namely G α_q and G $_i$, respectively (9, 13, 16, 18, 19). In contrast, thrombin is a strong agonist that is produced from the enzymatic cleavage of prothrombin (20). Further, thrombin receptors are separated into two different GPCR's (in humans) which are identified as PAR-1 and PAR-4, and they each engage a different signaling pathway: G α_q , G $_i$, G $\alpha_{12/13}$ and G α_q , G $\alpha_{12/13}$, respectively (9, 13, 18).

Section 1.1.3. G-protein coupled receptors signaling

The GPCRs are composed of a single polypeptide that is folded into a double helix of seven segments, which is transmembrane in nature, and they are coupled to heterotrimeric guanine-nucleotide binding-proteins (G-proteins), composed of an α , β , and γ subunits, belonging to the G $_q$, G $_{12/13}$, and G $_i$ families. Upon ligand binding, the receptor allows an exchange of GDP for GTP in the α -subunit. The exposed α -subunit, in case of G $_q$ for example activates an effector, " β isoform of phospholipase C" (PLC- β), which cleaves the membranous phospholipid "Phosphatidylinositol biphosphate" (PIP₂), thus, separating them into Inositol triphosphate (IP₃) and diacylglycerol (DAG). IP₃ will then bind into its receptor in the endoplasmic reticulum, which will raise the levels of Ca²⁺ while simultaneously decrease cyclic adenosine-3',5'-monophosphate (cAMP).

Following, Ca^{2+} calmodulin will bind to calmodulin-dependent protein kinase and start protein phosphorylation. Similarly, DAG will bind to protein kinase C and activate protein phosphorylation. The GTPase activity of the α -subunit promotes reassociation with $\beta\gamma$ to terminate ligand induced signaling (9, 13, 18, 21-25).

The function of each agonist is dependent on the specific G-protein subunit i.e. $\text{G}\alpha_q$'s effector-as describe above- is PLC- β which increases IP_3 (inositol-1,4,5-trisphosphate) / DAG. Similarly, $\text{G}\beta\gamma$ effector is PLC- β and PI3K- γ which increase IP_3/DAG and 3-PPIs, respectively (13). $\text{G}\alpha_{12/13}$ effector is p115-RhoGEF whose function is actin cytoskeleton reorganization. $\text{G}\alpha_s$ and $\text{G}\alpha_i$ effector is adenylate cyclase, and upon activation of their corresponding GPCR, the cyclic adenosine monophosphate (cAMP) levels increase or decrease, respectively (9, 13, 18).

Other platelet agonists bind to their own GPCR; e.g. TXA_2 binds to the thromboxane receptor, which couples to G_q and $\text{G}_{12/13}$ (13, 18), whereas 5-HT binds to 5-HT_{2A} Receptor, which couples with G_q (26).

Section 1.2. E-cigarettes

Electronic cigarettes/e-cigarettes are electronic nicotine delivering systems (ENDS). The e-cigarette user generates a mixture of vapor (derives from flavored or non-flavored liquids) and nicotine that is inhaled in the form of aerosol (27). The nicotine containing or free liquid normally utilized in e-cigarettes is commonly known as e-liquid. For certain types of e-cigarette devices (e.g., JUUL), the e-liquid is found in pods that are used in the vaping process. Often, e-liquids are composed of flavoring, nicotine, glycerin, and propylene glycol (27). Even with all existing different designs of e-cigarettes, e-cigarettes

share common functions and compositions i.e. a cartridge (filled with e-liquid), a rechargeable lithium battery, and a vaporization chamber (27, 28). Usually, the e-cigarette device has a sensor in the mouth piece, which will activate the atomizer when there is airflow (27, 28). Further, the atomizer vaporizes the e-liquid in the vaporizing chamber and delivers the aerosol mixture to the lungs (27, 28).

Currently, there are first, second, third, and fourth generation of e-cigarettes devices. First-generation e-cigarettes look like a traditional cigarette with no refillable cartridge and a low voltage (3.7 volts) (28, 29). Due to its low voltage output and low nicotine delivery, new users are more susceptible to use this device. Often, rechargeable and disposable e-cigarettes are considered first-generation e-cigarettes (28, 30). Smaller devices like the first-generation e-cigarettes had low battery life. Similarly, second-generation e-cigarettes still keep a somewhat traditional cigarette look, but now with adjustable voltage (3-6 volts), high tank capacity, and refillable cartridges (28, 30, 31). Due to its high voltage output, users can inhale higher puff volumes compared to the first-generation. In contrast, third-generation e-cigarettes now have a bulky look and are heavy, with refillable cartridges, longer battery life/size and adjustable voltage (28, 30). Fourth-generation devices can control temperature and airflow. Users utilizing fourth-generation devices can inhale serious amounts of e-liquid per use (28).

Section 1.2.1. E-cigarette JUUL

With popular demand, the e-cigarette market has kept increasing, thus, new devices continue to be manufactured. Recently, the JUUL e-cigarette brand has attained wide popularity among smokers, non-smokers, and especially the youth (32-34). The JUUL e-cigarette device is compact, low weight, user friendly, has good battery life, and creates

a small vapor cloud (35, 36). The JUUL e-liquid is often called the JUUL pod. Each pod contains ~0.7ml with 3% or 5% nicotine by weight. According to JUUL labs, each JUUL pod is composed of glycerol, propylene glycol, flavors, nicotine, and benzoic acid (37).

Currently, the JUUL e-cigarette is marketed as an e-cigarette device with a higher safety profile than traditional cigarettes (38). However, this statement is not evidence based and to our knowledge, there is a lack of information and studies regarding the safety profile of the JUUL e-cigarette device in the context of cardiovascular system. The state of regulatory laws (or lack of) for the JUUL e-cigarette is alarming as new young users continue to use this device (32-34). To this end, it is of great importance to investigate and establish the safety profile of JUUL e-cigarette, to not only educate the public but to also inform new safety/ regulatory laws.

Section 1.3.1. Serotonin

Serotonin (5-Hydroxytryptamine or 5-HT) is a weak agonist to platelet aggregation, yet, is an important regulator of hemostasis and thrombosis (39). Serotonin is found in the platelets granules and is released upon platelet activation (39). When released, serotonin induces vasoconstriction via modulation of endothelial cells and nitric oxide(39). Serotonin is also known to enhance platelet aggregation in the presence of other agonists like ADP (40-42). For normal hemostasis, proper platelet activation and recruitment is necessary. Improper recruitment and excessive aggregability of platelets can lead to thrombosis and thromboembolism (43-46).

The 5-HT_{2A} receptor (5-HT_{2AR}), a subtype of 5HT₂, plays an important role in platelet function (47). In addition, 5-HT_{2AR} is also a GPCR (48), and is involved in the

development of different kinds of cardiovascular disorders (49, 50). Even though there is much information known about 5HT_{2A}R in pathogenesis of thrombotic disease (41, 49-54), there are no antagonists currently available for thrombosis/platelet related clinical use which target this specific pathway (53-55). Thus, it is vital to understand the structural biology of 5HT_{2A}R and signaling transduction mechanisms to develop a drug that can modulate 5HT_{2A}R activation.

CHAPTER II: JUUL E-Cigarette Increases the Risk of Thrombosis and Enhances Platelet Function in Mice.

Section 2.1. Abstract

Background: Smoking is the main preventable cause of death in United States and is associated with serious cardiovascular health consequences, including thrombosis disease. In recent years, electronic-cigarettes (i.e. e-cigarettes) have attained wide popularity among smokers, non-smokers, pregnant females, and even youth. One particular e-cigarette that has gained popularity over the past 2 years is the JUUL. JUUL labs has grown expeditiously to the point of attaining \$150 million US dollars in retail sales, which accounts for 40% of the e-cigarette retail market share. JUUL's popularity is alarming; especially among youth. Interestingly, there is no information/studies regarding the effect of JUUL on cardiovascular diseases, specifically in the context of modulation of platelet activation. Thus, it is important to discern the cardiovascular disease health risks associated with JUUL. **Methods:** We utilized a passive e-vape™ vapor inhalator system where C57BL/6J mice (10-12 weeks old) were exposed to JUUL e-cigarette vape/smoke. Menthol flavored JUUL pods containing 5% nicotine by weight were used as the e-liquid. Mice were exposed to a total of 70 puffs per day for 2 weeks; 3 secs puff duration, 25 secs puff interval, and 50 ml puff volume. We analyzed the effects of JUUL exposed mice relative to those exposed to clean air, in the context of platelet function *in vitro* and thrombogenesis *in vivo*. **Results:** Our results indicate that short-term exposure to JUUL e-cigarette causes hyper-activation of platelets *in vitro* and shortens the thrombus occlusion as well as hemostasis/bleeding time. **Conclusion:** Our findings show for the first time that short-term exposure to JUUL E-cigarette can increase the risk of

thrombogenic events and can alter physiological hemostasis; in part by modulating platelet function; in mice.

Section 2.2. Introduction

It is well established that tobacco smoking is associated with cardiovascular disease/CVD, which is the leading cause of death in the world (1, 56, 57). Being the single most preventable risk factor for the development of CVD (57, 58), traditional cigarette smoking/usage has declined and new products have been introduced into the market (59-62). To this end, electronic-cigarettes (e-cigarettes) have attained wide popularity in recent years, due to the perception of being a safer option/alternative relative to tobacco smoking, with minimal or no harm (38). As the e-cigarette market keeps growing at a fast pace, hundreds of devices/models continue to be invented. One particular e-cigarette device that has gained significant popularity over the past 2 years is known as “JUUL” (32-34). JUUL sales have grown expeditiously to the point of attaining \$150 million US dollars in retail sales, which accounts for 40% of the e-cigarette retail market share (63). It has a novel slim USB-like design that makes it easy to use and carry, and it also comes with prefilled e-liquid pods and is available in various flavors (64, 65). The unique design and appealing nature of the device and flavors along with the advertisement/marketing campaign attracts smokers, non-smokers, and even the youth (35, 36, 66). Of particular concern is the fact that the youth has the highest increase in e-cigarettes usage (67, 68), especially the JUUL device (65, 69-72). Thus, over 3.6 million kids have used e-cigarettes in 2018, which corresponds to 78% and 48% increase in usage among high school and middle school students, respectively, compared to 2017 (67, 68, 73). In fact, the Food and Drug Administration (FDA) raised concerns regarding JUUL’s popularity in young

communities and the potential for creating a new generation of smokers (38, 74). Based on these considerations, it is paramount to establish the safety of exposure to JUUL e-cigarette, including in the context of cardiovascular disease. To this end, limited studies have evaluated the impact of traditional e-cigarettes on the genesis of thrombosis-based CVD. Nonetheless, we have previously shown that short-term e-cigarette exposure can alter physiological hemostasis and increase the risk of thrombosis, via modulating platelet function in mice (75). Additionally, a recent crossover study that was conducted on tobacco smokers and nonsmokers found that acute use of e-cigarettes enhanced platelet aggregation (76). To our knowledge, there is no information regarding the impact of JUUL e-cigarette on the cardiovascular system.

JUUL has certain/unique features and does not resemble the traditional e-cigarette as the device is circuit and temperature controlled and generates a small cloud. Furthermore, the e-liquid composition is also different, as it contains a nicotine salt and higher concentrations of nicotine (3% and 5% by volume) (64, 77). According to JUUL labs, each e-liquid JUUL pod is intended to give 200 puffs, which equals one pack of combustible cigarettes in terms of the delivered nicotine concentration (78). Furthermore, the use of the salt results in higher amount of nicotine being delivered to users. To this end, a recent study did in fact show that youth are exposed to higher concentrations of nicotine when they use JUUL, compared to combustible cigarettes (64, 79). Therefore, we characterized the impact of JUUL exposure on thrombogenesis and platelet function- in mice- utilizing a whole-body exposure protocol that mimics real life JUUL users. Our findings demonstrate that two weeks exposure to JUUL e-cigarette increases the risk of thrombosis and enhances hemostasis, in mice. In addition, JUUL exposure enhances

platelet activity as reflected by enhanced aggregation, secretion, and integrin GPIIb/IIIa activation. These findings indicate that the JUUL e-cigarette is not safe as people believe. Further studies are needed to shed more light on its harmful effects to the cardiovascular health.

Section 2.3. Materials and Methods

Section 2.3.1. Materials and Reagents

JUUL device and JUUL Pods (5% nicotine and menthol flavoring) were purchased from the JUUL Labs, Inc. (www.juul.com). Stir bars and other disposables were purchased from Chrono-Log Corporation (Havertown, PA). ADP and thrombin were purchased from Sigma Aldrich (St. Louis, MO). Fluorescein isothiocyanate (FITC)-conjugated anti-P-selectin and FITC-conjugated Annexin V were purchased from Cell Signaling Technology, Inc (Danvers, MA). Phycoerythrin (PE)-conjugated JON/A antibody was obtained from Emfret analytics (Würzburg, Germany). The Mouse/Rat Cotinine ELISA kit was from Calbiotech (El Cajon, CA). Platelet count was determined using an automated hematology analyzer (Drew Scientific Dallas, TX). The primary antibodies (ERK, pERK, Akt, and pAkt) were purchased from cell signaling Technology, Inc. (Danvers, MA). Other reagents were of analytical grade.

Section 2.3.2. Animals

C57BL/6J (10-12-week-old male) mice were obtained from Jackson Laboratory (Bar Harbor, ME). Mice were housed in groups of 1–5 at 24 ° C, under 12/12 light/dark cycles, with access to water and food ad libitum. All animal experimental protocols were approved

by the Institutional Animal Care and Use Committee (IACUC) of The University of Texas at El Paso.

Section 2.3.3. JUUL E-cigarette Exposure Protocol

C57BL/6 mice (10-12 weeks old males) were exposed to a total of 70 puffs per day for a period of 2 weeks. Puff duration was 3 seconds (puff volume was 50 ml) with puff intervals of 25 seconds. These conditions mimic real-life exposure scenarios (75, 80-82). As for the control mice, they are matched in terms of age and sex to the JUUL e-cigarette exposed mice and were exposed to clean air. The JUUL e-cigarette exposed and control mice were deprived of food and water during exposure. The apparatus used to generate the aerosol (e-vape) is a custom-made bench-top e-Vape™ vapor inhalation system for rodents (La Jolla Alcohol Research, Inc). The system has four chambers each connected to its own “mode box”. The “mode box” is custom made with a USB outlet to be compatible with the JUUL device, and is connected to a controller that allows us to automatically pre-determine the following experimental conditions: the puff time/duration, puff interval (time between puffs), and/or number of puffs. In terms of the JUUL pods, each contained 0.7 mL of e-liquid with 5% nicotine by weight and menthol flavoring (32, 83).

Section 2.3.4. Methods

The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. Because there are no specific study materials per se, requests for data, and the vaping protocol will be honored on a case-by-case basis.

Section 2.3.5. Cotinine Assay

The urinary levels of cotinine, a metabolite of nicotine, were measured in both JUUL and clean air–exposed mice, using the Cotinine Direct ELISA kit as per the manufacturer’s instructions.

Section 2.3.6. *In vivo* Thrombosis Model

JUUL e-cigarette and clean air exposed mice were anesthetized by IP injections of avertin. Then, the left carotid artery was exposed and cleaned, and baseline carotid artery blood flow was measured with Transonic micro-flowprobe (0.5 mm, Transonic Systems Inc., Ithaca, NY). After stabilization of blood flow, 7.5% ferric chloride (FeCl_3) was applied to a filter paper disc (1-mm diameter) that was immediately placed on top of the artery for 3 min. Blood flow was continuously monitored for 30 min, or until blood flow reached stable occlusion (zero blood flow for 2 min). Data was recorded and time to vessel occlusion was calculated as the difference in time between stable occlusion and removal of the filter paper (with FeCl_3). An occlusion time of 30 min was considered as the cut-off time for the purpose of statistical analysis.

Section 2.3.7. Tail Bleeding Time Assay

Hemostasis was examined using the tail transection technique. Mice were anesthetized and placed on a 37 °C homeothermic blanket. Tail was transected 5 mm from the tip using a sterile scalpel. After transection, the tail was immediately immersed in saline (37 °C, constant temperature) and the time to bleeding cessation was measured. Bleeding time of 15 min was considered as the cut-off time for the purpose of statistical analysis.

Section 2.3.8. Murine Platelet-Rich Plasma Preparation

Clean air– or JUUL e-cigarette–exposed mice were anesthetized, and blood was collected from the heart. Coagulation was inhibited by 0.38% sodium citrate solution (Fisher Scientific, Hampton, NH). Blood was centrifuged (237g for 15 minutes) at room temperature, and the platelet-rich plasma was then collected. Platelets were counted with the HEMAVET® and their count adjusted to 7×10^7 platelets/mL before each experiment.

Section 2.3.9. Washed Platelet Preparation

Washed platelets were prepared as described previously (21, 84, 85). Blood was drawn from C57BL/6J mice (10–12 weeks old) as discussed above and mixed with phosphate-buffered saline, pH 7.4, incubated with PGI₂ (10 ng/mL; 5 minutes), followed by centrifugation at 237x g for 10 minutes at room temperature. Platelet-rich plasma was recovered, and platelets were pelleted at 483x g for 10 minutes at room temperature. The pellets were resuspended in HEPES/ Tyrode buffer (20 mmol/L HEPES/KOH, pH 6.5, 128 mmol/L NaCl, 2.8 mmol/L KCl, 1 mmol/L MgCl₂, 0.4 mmol/L NaH₂PO₄, 12 mmol/L NaHCO₃, 5 mmol/L Dglucose) supplemented with 1 mmol/L EGTA, 0.37 U/mL apyrase, and 10 ng/mL PGI₂. Platelets were then washed and resuspended in HEPES/Tyrodes (pH 7.4) without EGTA, apyrase, or PGI₂. Platelets were counted using the HEMAVET® and adjusted to the indicated concentrations.

Section 2.3.10. *In vitro* Platelet Aggregation

Platelet-rich plasma from clean air– or JUUL e-cigarette–exposed mice was activated with 1 μM ADP or 0.1 U/ml thrombin. Platelet aggregation was measured by the

turbidometric method using a model 700 aggregometer (Chrono-Log Corporation). Each experiment was repeated at least 3 times, with blood pooled from 5-8 mice each time.

Section 2.3.11. Flow Cytometric Analysis

Flow cytometric analysis was performed as previously prescribed (21). Washed platelets were stimulated with ADP (1 μ M), or thrombin (0.1 U/ml). The reactions were stopped by fixing the platelets with 2% formaldehyde for 30 min at room temperature. Finally, platelets were incubated with FITC-conjugated Annexin V and anti- P-selectin, or Jon/A PE-conjugated antibodies at room temperature for 30 min in the dark. Finally, the platelets were diluted 2.5-fold with HEPES/ Tyrode buffer (pH 7.4). The samples were transferred to FACStubes and fluorescent intensities were measured using a BD Accuri C6 flow cytometer and analyzed using CFlow Plus (BD Biosciences, Franklin Lakes, NJ).

Section 2.3.12. Immunoblotting

Immunoblot was carried out as described before (85). Briefly, clean air- or JUUL- exposed washed platelets were stimulated with ADP (1 μ M) or thrombin (0.1 U/ml) for 3 minutes followed by lysis with 1X sample buffer. Next, proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to Immobilon-P PVDF membranes (Bio-Rad, Hercules, CA). Membranes were then probed with the primary antibodies (ERK, pERK, Akt, and pAkt) and visualized with horseradish peroxidase-labeled anti-rabbit or anti-mouse immunoglobulin G as required. The antibody binding was detected using enhanced chemiluminescence substrate (Thermo Scientific, Rockford, IL). Images were obtained with ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA), and quantified with Image Lab software Version 4.1 (Bio-Rad).

Section 2.3.13. Statistical Analysis

All experiments were performed at least three times. Analysis of the data was performed using GraphPad PRISM statistical software (San Diego, CA) and presented as mean \pm SD. The Mann-Whitney test was used for the evaluation of differences in mean occlusion and bleeding times. Analysis was also conducted using the t-test and/or one-way ANOVA with Tukey's multiple regression comparison as post hoc were used as applicable. Significance was accepted at $P < 0.05$, unless stated otherwise.

Section 2.4. Results

Section 2.4.1. JUUL E-Cigarette Exposure Systematically Delivers Nicotine

In order to verify if our whole-body exposure model does systematically deliver nicotine to the mice, cotinine was measured due to the fact that it is a major metabolite of nicotine, thus serving as a marker of nicotine delivery (86, 87). Therefore, urinary cotinine levels were measured using ELISA, and our data showed significant levels of cotinine in the urine of JUUL e-cigarette exposed mice, whereas it was undetectable in the clean air control mice (Fig. 2.1.).




Figure 2.1. JUUL exposure results in systemic delivery of nicotine (cotinine).

Urinary cotinine levels from JUUL and clean air exposed mice (clean air, n = 5; and JUUL, n = 5; ****P<0.0001).

Section 2.4.2. JUUL E-Cigarette Exposed Mice Exhibit Enhanced Physiological Hemostasis and Thrombus Formation

In terms of characterizing the negative CV effects of the JUUL e-cigarette, we initially investigated its capacity to modulate physiological hemostasis by utilizing the tail bleeding time assay. Our findings show that JUUL-exposed mice have significantly shortened tail bleeding time compared to mice exposed to clean air (Fig. 2.2.A). Next, we examined the thrombotic effect of JUUL e-cigarette exposure by implementing the carotid artery injury-induced thrombosis model. We observed that JUUL-exposed mice have remarkably shortened occlusion time compared to their controls (Fig. 2.2.B). These results indicate that JUUL e-cigarette exposure increases the risk of thrombosis and enhances physiological hemostasis.




Figure 2.2. JUUL exposure shortens the tail bleeding and occlusion times. (A) JUUL e-cigarette and clean air exposed mice were subjected to the tail bleeding time assessment. Each point represents the tail bleeding time of a single animal (clean air, n = 7; and JUUL, n = 7; ***P<0.001). (B) JUUL e-cigarette and clean air exposed mice were

subjected to the ferric chloride-induced thrombosis model. Each point represents the occlusion time of a single animal (clean air, n = 5; and JUUL e-cigarette, n = 5; **P<0.01).

Section 2.4.3. JUUL E-Cigarette Exposure Enhances ADP-, and Thrombin-Induced Platelet Aggregation

We have previously shown that e-cigarette exposure modulates platelet function (75). Thus, we sought to investigate whether the JUUL e-cigarette exposure would also produce platelet effects. Consequently, we assessed the effects of JUUL e-cigarette exposure on platelet aggregation induced by “two” separate G-protein coupled receptors, namely those activated by ADP and thrombin. Our data revealed that exposure to JUUL e-cigarettes results in higher ADP-induced platelet aggregation, in comparison to clean air control platelets (Fig. 2.3.A). Similarly, thrombin-induced platelet aggregation was also elevated/enhanced in the JUUL e-cigarette exposed platelets (Fig. 2.3.B). These results suggest that JUUL e-cigarette exposure can lead to platelet hyperactivity.




Figure 2.3. Platelet aggregation is enhanced in JUUL exposed mice. Platelets from JUUL e-cigarette and clean air exposed mice were stimulated with (A) ADP (1 μmol/L), or (B) thrombin (0.1 U/ml). The aggregation response was measured using an

aggregometer. Each experiment was repeated 3 times, with blood pooled from 5-8 mice each time.

Section 2.4.4. JUUL E-Cigarette Exposure Enhances ADP-, and Thrombin-Induced Platelet Secretion

Agonist-induced exocytosis or granules release plays a very important role in the amplification of initial platelet activation during primary hemostasis (88-90). Accordingly, we determined if JUUL e-cigarette exposure exerts any impact on dense and α granule secretion. In line with our aggregation data, we observed enhanced ATP secretion from platelets obtained from the JUUL e-cigarette exposed mice in response to ADP (Fig. 2.4.A) and thrombin (Fig. 2.4.B) agonist stimulation, when compared to platelets from the clean air exposed mice. Moreover, JUUL e-cigarette exposed platelets had significantly higher ADP-, and thrombin-triggered P-selectin expression (Fig. 2.4.C).




Figure 2.4. Platelet dense and α granule secretion are enhanced in JUUL exposed mice. Platelets from JUUL e-cigarette and clean air exposed mice were incubated with

luciferase luciferin (12.5 μ L), then were stimulated with (A) ADP (1 μ mol/L), or (B) thrombin (0.1 U/ml). ATP release (dense granules) was detected as luminescence and measured by a lumi aggregometer. (C) Platelets from JUUL e-cigarette and clean air exposed mice were washed, before stimulation with 1 μ mol/L ADP, or 0.1 U/ml thrombin. Platelets were incubated with fluorescein isothiocyanate conjugated CD62P antibody, and the fluorescent intensities were measured by flow cytometry. The average mean fluorescence intensities are showed (****P<0.0001). Each experiment was repeated 3 times, with blood pooled from 5-8 mice each time.

Section 2.4.5. JUUL E-Cigarette Exposure Enhances Agonist-Induced Integrin GPIIb/IIIa Activation and Phosphatidylserine Exposure

We next investigated if there is a commensurate increase in integrin GPIIb/IIIa (α IIb β 3) activation in the JUUL e-cigarette exposed platelets, given their increased aggregation phenotype (91, 92). We found that JUUL e-cigarette exposed platelets had an enhanced agonist-mediated activation of GPIIb/IIIa, when compared to clean air exposed platelets (Fig. 2.5.A). Moreover, agonist-mediated phosphatidylserine (PS) expression, which is a critical element for efficient activation of the coagulation cascade and essential aspect of clot formation, was also found to be enhanced in the JUUL platelets (Fig. 2.5.B).




Figure 2.5. Integrin GPIIb/IIIa activation and phosphatidylserine (PS) exposure are increased in JUUL exposed mice. Platelets from JUUL e-cigarette and clean air exposed mice were washed, before stimulation with 1 $\mu\text{mol/L}$ ADP, or 0.1 U/ml thrombin. Platelets were incubated with phycoerythrin-conjugated JON/A antibody, and the fluorescent intensities were measured by flow cytometric analysis (A); (**** $P < 0.0001$). Platelets were incubated with fluorescein isothiocyanate-conjugated Annexin V antibody, and the fluorescent intensities were measured by flow cytometric analysis (B). Average mean fluorescence intensities shown (**** $P < 0.0001$). Each experiment was repeated 3 times with blood collected from 5-8 mice each time.

Section 2.4.6. JUUL E-Cigarette Exposure Enhances Akt and ERK Activation

Finally, and in light of the functional data indicating platelet hyperactivity, we sought to determine if biochemical markers of platelet activation would also be elevated as a result of JUUL e-cigarette exposure. Indeed, Akt and ERK phosphorylation were found to be elevated in the JUUL platelets, in response to ADP (1 μM ; Fig. 2.6.).




Figure 2.6. Platelet Akt (protein kinase B) and ERK (extracellular signal-regulated kinases) activation (phosphorylation) is enhanced in JUUL exposed mice. Platelets from JUUL and clean air–exposed mice were prepared and washed. (A) Platelets were stimulated with 1 $\mu\text{mol/L}$ adenosine diphosphate (ADP) for 3 min, and proteins were lysed using 1 \times sample buffer. Proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis before being subjected to immunoblotting with anti-Akt, anti-pAkt (Ser473), anti-ERK, and anti-pERK antibodies. (B) Data quantification of ADP-induced ERK and Akt phosphorylation (**** $P < 0.0001$; *** $P < 0.001$). Each experiment was repeated at least 3 times with blood collected from a group of 5-8 mice each time.

In summary, our data provides evidence that two week exposures to JUUL e-cigarettes vapes results in enhanced *in vitro* and *in vivo* platelet function, which was also confirmed by biochemical means.

Section 2.5. Discussion

The JUUL e-cigarette has been gaining popularity at an alarming rate since its introduction into US market in 2015, and by 2018 has overtaken more than half of the e-cigarette market (33, 35, 93). In this connection, it was marketed by JUUL labs, the manufacturer, as an e-cigarette device with a higher safety profile than traditional cigarettes (38); which we know is not supported by evidence. It has a unique USB- like design and comes with pre-filled pods that makes it appealing to use and easy to carry. Consequently, its use increased significantly among smokers and non-smokers, but also especially (and of more concern) among the youth (62, 83, 94). In term of the cardiovascular safety of e-cigarettes, we recently showed that exposure to traditional e-cigarette enhances physiological hemostasis and increases risk of thrombosis via modulating platelet function, in adult mice (75). However, whether the JUUL e-cigarette exerts negative health effects, namely increases the risk of thrombosis-dependent cardiovascular disorders remains to be investigated. Indeed, given the wide popularity and the unique features of JUUL e-cigarette, it is paramount to establish the cardiovascular safety of these devices. Thus, this issue was investigated by employing a mouse whole-body *in vivo* exposure model and a protocol that mimics real-life exposure scenarios of a daily JUUL user (69). It has been recently reported that daily JUUL users consume 10 pods per one month, which equals one pod every three days. Since each pod can generate 200 puffs, we choose to expose mice to 70 puffs per day to resemble human settings (69). Given that JUUL e-cigarette has only recently been introduced into the market, human studies related to its effect on the general health, and the cardiovascular system (CV) in specific are non-existent. Thus, mouse models can serve

as a readily available and practical tools to provide rather rapid answers to some of the safety questions, which may need months and/or years to establish in human studies. Furthermore, human studies are complicated by the variability of e-liquids and various flavors used, patterns of use, user's experience, and the concomitant use of other tobacco products, which makes it hard to draw a conclusion. Notably, given these challenges in human studies, the current mouse model gives flexibility in mimicking many aspects of human use, and the literature does support the fact that mouse studies do "map" very well to humans in the context of tobacco exposure (75, 80-82).

Initially, we validated our model by measuring the levels of cotinine, a key biomarker of nicotine exposure (95, 96), in urine samples of JUUL e-cigarette and clean air exposed mice. The cotinine levels increased significantly in JUUL e-cigarette exposed mice, whereas it was undetectable in the clean air exposed mice. Indeed, these high cotinine levels are not surprising given the fact that each JUUL pod (200 puffs) contains a high concentration of nicotine (5% by weight); which is equivalent to 1 pack of cigarettes (97, 98). Furthermore, the use of nicotine salt results in high amounts of nicotine being delivered to users as the salt masks the bitter taste of nicotine. Consistent with our finding, a recent study showed that youth are exposed to higher concentrations of nicotine when they use JUUL, compared to combustible cigarettes (99). Taken together, JUUL e-cigarette delivers a high amount of nicotine to users, which raises concerns regarding potential negative impact of nicotine, especially among youth users (98); which warrants investigation. Of note, while e-cigarettes have potential toxicants, such as nicotine, propylene glycol/glycerol, and flavors (100, 101), the JUUL pods contain nicotine salts, whose toxicity is virtually unknown.

As for the effects of JUUL on the genesis of thrombosis-dependent CVD, studies are non-existent. Our mouse model data demonstrated for the first time that exposure to JUUL (two weeks) increases the risk of thrombosis, as reflected by the prolonged occlusion time compared to control mice. Additionally, JUUL exposure altered physiological hemostasis as evidenced by the shortened tail bleeding time. A similar prothrombotic phenotype was also observed in short term exposure to traditional e-cigarettes (75). In support of these findings, a recent meta-analysis concluded that e-cigarettes should not be marketed as “cardiovascularly” safe devices as more evidence needs to be collected (102). Collectively, our findings clearly indicate that JUUL e-cigarettes pose a negative cardiovascular (thrombotic) health impact contrary to the claimed safety by JUUL labs (38).

In light of the observed prothrombotic phenotype and since platelets are key players in thrombus formation (103, 104), we sought to investigate the impact/effects of JUUL e-cigarette on platelet function. Our data revealed that JUUL exposure enhances platelet function, including aggregation, secretion, integrin GPIIb/IIIa activation, phosphatidylserine (PS) exposure, compared to clean air. Moreover, the phosphorylation of Akt and ERK, which serve as biochemical markers of platelet activity, was enhanced in response to JUUL e-cigarette exposure. These data indicate that JUUL e-cigarette exposed platelets are hyperactive, which could explain- at least partially, the observed prothrombotic phenotype. Supportingly, our previously published data with traditional e-cigarette exposure showed similar trends of increased platelet function, in mice (75). These data are also consistent with a recent human study in which acute e-cigarette use was found to increase platelet activation (76).

Section 2.6. Conclusion

In conclusion, our study revealed for the first time that whole-body JUUL e-cigarette exposure alters physiological hemostasis and increases the risk of thrombosis, in mice; in part by modulating platelet function. Importantly, these findings provide clear/initial evidence that the JUUL e-cigarette is not safe as currently claimed, and should be the focus of further investigations. Additionally, our study should help increase awareness of the negative health consequences of these devices, especially among the youth, including those who had never smoked before but tried JUUL with the perception that these devices are safe. Given the current epidemic of e-cigarette use, specifically JUUL, we expect our data to help guide/inform the FDA in instituting and implementing stricter regulations to limit the use of JUUL devices.

CHAPTER III: A Novel Antibody Targeting The Second Extracellular Loop of The Serotonin 5-HT_{2A} Receptor Inhibits Platelet Function.

Section 3.1. Abstract

Background: Serotonin (5-hydroxytryptamine or 5-HT) is known to be a weak agonist involved in thrombus formation. 5-HT cannot induce platelet aggregation on its own. Yet, when the secreted 5-HT binds to its G-protein Coupled Receptor (GPCR; i.e. 5HT_{2A}R), 5-HT acts to amplify platelet functional responses (e.g., aggregation). Thus, 5HT_{2A}R mediated responses are more involved in the secondary amplification of platelet aggregation in the growing thrombus. Therefore, 5-HT can be seen as a weak inducer of platelet activation, but it is an important amplifier of aggregation triggered by agonists such as ADP, collagen, and epinephrine, thereby enhancing thrombogenesis. 5HT_{2A}Rs are of clinical interest to the medical community as they are implicated in cardiovascular diseases. Efforts to develop antagonists for 5HT_{2A}R as therapy in cardiovascular diseases have thus far failed due to these reagents having deleterious side-effects and/or to lack of selectivity. **Methods:** In light of research efforts that identified that the 5HT_{2A}R ligand binding domain lies in the second extracellular loop (EL2; P²⁰⁹-N²³³), we developed an antibody, i.e. referred to as 5HT_{2A}RAb against the EL2 region Q²¹⁶-N²³³, and characterized its pharmacological activity. Thus, we utilized C57BL/6J mice (10-12 weeks old) to analyze the inhibitory effects of the 5HT_{2A}RAb on platelet activation *in vitro*, *ex vivo*, and on thrombogenesis *in vivo*. **Results:** Our results indicate that the 5HT_{2A}RAb inhibits platelet aggregation *in vivo*, *ex vivo*, and that it prolongs the thrombus occlusion time, but it did not modulate the tail bleeding time, in mice. **Conclusion:** Our findings

document that 5HT_{2A}RAb exhibits platelet function blocking-activity and protects against thrombogenesis without impairing normal hemostasis.

Section 3.2. Introduction

Platelets are indispensable to physiological hemostasis (105, 106). When a blood vessel is injured, platelets are able to interact with the unmasked/exposed subendothelial matrix, which thereby leads to platelet adherence and activation (107, 108). Consequently, a number of intraplatelet signaling pathways are triggered, which result in a rise in intracellular calcium levels; secretion of granule content (109, 110) (e.g., serotonin/5HT and ADP); as well as liberate arachidonic acid (AA) from the membrane phospholipids (109). While ADP in turn interacts with its P2Y₁ and P2Y₁₂ G-protein coupled receptors (GPCRs), AA is acted upon by cyclooxygenase (COX-1) to produce PGH₂, which is metabolized by thromboxane A₂ synthase into TXA₂ (111, 112). The latter binds to its own GPCR (113-115), and thereby activates platelets. Moreover, another important aspect of platelet signaling involves binding of the secreted serotonin (5-hydroxytryptamine or 5-HT) to its platelet 5HT_{2A}R GPCR in order to amplify platelet functional responses (e.g., aggregation) (116). Thus, several positive feedback loops are initiated to intensify the extent of aggregation by means of enhancing platelet responsiveness as well as recruiting other platelets to the site of injury, in order to achieve formation of a stable clot (116).

Although platelet activation is a vital component of hemostasis, improper activation and aggregation may lead to thrombosis and thromboembolism (43-46). Consequently, anti-thrombotic drug development efforts have focused on the discovery of reagents/drugs that modulate activation of platelets by their agonists (117, 118). The serotonin 5HT_{2A}R,

which couples to Gq (119, 120), recently has been under drug targeting scrutiny as of late (55). While 5HT itself is a weak stimulator of platelet activation, it does however potentiate aggregation triggered by separate agonists, thereby enhancing thrombogenesis (24, 25). Another attractive aspect of targeting 5HT_{2A}R for therapeutic purposes centers on the notion that its anti-thrombotic activity and bleeding time adverse events can be separated (which has been demonstrated previously albeit the mechanism remains unknown to date (53-55)). To this end, a host of antagonists for 5HT_{2A}R were developed throughout the years and investigated for their pharmacological activity (53-55, 121-123). Unfortunately, none have been approved for clinical use due to significant toxicity, and/or lack of selectivity for 5HT_{2A}R, amongst others. One discernable reason for failure of 5HT_{2A}R antagonism thus far seems evident, as these agents were designed empirically, without “regard” to the 5HT_{2A}R binding domains information. Therefore, it is critical to understand the structural biology and signaling of 5HT_{2A}R. In this connection, mapping of the 5HT_{2A}R ligand binding domain revealed that the ligand binding domain resides in the second extracellular loop (EL2) of the receptor protein, namely (P²⁰⁹-N²³³) (124-126).

Based on these considerations, in the present study, we custom-made and characterized the antiplatelet activity of a potentially 5HT_{2A}R-function-blocking antibody that targets its EL2 region (abbreviated as 5HT_{2A}RAb). Our studies revealed that this 5HT_{2A}RAb indeed inhibited serotonin-enhanced ADP-induced human/mice platelet aggregation *in vitro*, and *ex vivo* in mice. Also, 5HT_{2A}RAb inhibited serotonin-enhanced ADP-stimulated platelet secretion, glycoprotein (GP) IIb/IIIa activation, and phosphatidylserine (PS) exposure. The 5HT_{2A}RAb was also found to displace binding of the radiolabeled 5HT_{2A}R antagonist [³H]Ketanserin from its binding sites; this effect was reversed by preabsorption of

5HT_{2A}RAb with its cognate peptide (Q²¹⁶-N²³³). Moreover, as for its *in vivo* activity, mice treated with 5HT_{2A}RAb had a significantly prolonged occlusion time, but their bleeding time was no different from that of the controls.

Section 3.3. Materials and Methods:

Section 3.3.1 Materials and Reagents

Serotonin hydrochloride, and ADP were obtained from Sigma Aldrich (St. Louis, MO). Stir bars and other disposables were from Chrono-Log (Havertown, PA). FITC-conjugated Annexin V, anti-P-selectin, and PAC-1 antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA). The 5HT_{2A} receptor targeting polyclonal antibody, designated 5HT_{2A}RAb, was custom made and antigen-affinity purified by a commercial vendor, Abbiotec Inc (San Diego, CA). Platelet count was determined using an automated hematology analyzer (Drew Scientific Dallas, TX).

Section 3.3.2. Animals

C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, ME). Mice were housed in groups of 1–4 at 24⁰C, under 12/12 light/dark cycles, with access to water and food ad libitum. All experiments involving animals were performed in compliance with the institutional guidelines, and were approved by the Institutional Animal Care and Use Committee.

Section 3.3.3. Human and Murine Platelet Preparation

Blood was drawn from healthy volunteers who denied taking any medication for 1 week prior to collection, or from C57BL/6 mice (8–10 weeks old). Mice were anesthetized and blood was collected from the heart. Coagulation was inhibited by 3.8% w/v sodium citrate solution (1 part sodium citrate to 9 parts blood). Human or mouse platelet rich plasma (PRP) was obtained by centrifugation at room temperature. Platelets were counted with an automated hematology analyzer and their count adjusted to 7×10^7 platelets/ml, prior to each experiment. Washed human platelets were prepared as described in Karim et al (21). PRP was isolated in the presence of 0.37 units/ml apyrase and 10 ng/ml PGI₂ by centrifugation at 237g for 10 min at 20 °C. PRP was centrifuged at 483g for 10 min, and pelleted platelets were resuspended in HEPES/Tyrode's buffer (20 mMHEPES/NaOH, pH 6.5, 128 mM NaCl, 2.8 mM KCl, 1 mM MgCl₂, 5 mM D-glucose, 12 mM NaHCO₃, 0.4 mM NaH₂PO₄) containing 1 mM EGTA, 0.37 units/ml apyrase, and 10 ng/ml PGI₂. Platelets were washed and resuspended in HEPES/Tyrode's buffer (pH 7.4) without EGTA, apyrase, or PGI₂. The final platelet counts were adjusted to 7×10^7 platelets/ ml, unless otherwise indicated.)

Section 3.3.4. *In vitro* Platelet Aggregation

Human PRP was incubated with the 5HT_{2A}RAb for 5 min prior to experiments, except in case of the controls. Platelets were then activated with submaximal concentration of ADP (1 μM), in the presence or absence of 15 μM serotonin. Control experiments were conducted using the ADP agonist alone (10 μM). Platelet aggregation was measured by

the turbidometric method using a model 700 aggregometer (Chrono-Log Corporation, Havertown, PA). Each experiment was repeated at least 3 times, with blood collected from three different human donors, or pooled together from at least eight mice each time.

Section 3.3.5. *Ex vivo* Platelet Aggregation

Mice were injected with the 5HT_{2A}RAb (150 mM) or vehicle (deionized water) using the tail vein route once daily for 5 days; in an attempt to mimic chronic administration of these drugs in patients. Mice were sacrificed one hour post last injection, and their blood collected. Platelets (with counts adjusted as described before) were stimulated with 1 μ M ADP in the presence or absence of 15 μ M serotonin, and platelet aggregation was measured. Control experiments were conducted using the ADP agonist alone (10 μ M). Each experiment was repeated at least 3 times, with blood pooled from at least eight mice each time.

Section 3.3.6. Flow Cytometric Analysis

Human platelets (2×10^8) were incubated in the presence or absence of 5HT_{2A}RAb (150 nM) for 5 minutes. Platelets were stimulated with 1 μ M ADP in the presence or absence of 15 μ M serotonin. Control experiments were conducted using the ADP agonist alone (10 μ M). The reactions were stopped by fixing the platelets with 2% formaldehyde for 30 min at room temperature. Finally, platelets were incubated with FITC-conjugated Annexin V, anti- P-selectin, or PAC-1 antibodies at room temperature for 30 min in the dark. Finally, the platelets were diluted 2.5-fold with HEPES/ Tyrode buffer (pH 7.4). The samples were transferred to FACStubes and fluorescent intensities were measured using

a BD Accuri C6 flow cytometer and analyzed using CFlow Plus (BD Biosciences, Franklin Lakes, NJ).

Section 3.3.7. *In vivo* Thrombosis Model

These studies were performed as described previously (127, 128). Briefly, mice 8–10 weeks old received tail vein injections of the 5HT_{2A}RAb (150 nM) or vehicle once daily for 5 days, and were anesthetized with isoflurane. Then, the left carotid artery was exposed and cleaned, and baseline carotid artery blood flow was measured with Transonic micro-flowprobe (0.5 mm, Transonic Systems Inc., Ithaca, NY). After stabilization of blood flow, 7.5% ferric chloride (FeCl₃) was applied to a filter paper disc (1-mm diameter) that was immediately placed on top of the artery for 3 min. Blood flow was continuously monitored for 30 min, or until blood flow reached stable occlusion (zero blood flow for 2 min). Data was recorded and time to vessel occlusion was calculated as the difference in time between stable occlusion and removal of the filter paper (with FeCl₃). An occlusion time of 30 min was considered as the cut-off time for the purpose of statistical analysis.

Section 3.3.8. Tail Bleeding Time

Mice were tail vein injected with the 5HT_{2A}RAb (150 nM) or vehicle once daily for 5 days, before their hemostasis response was examined using the tail transection technique (127, 128). Briefly, mice were anesthetized and placed on a 37 °C homeothermic blanket. The tail was transected 5 mm from the tip using a sterile scalpel. After transection, the tail was immediately immersed in saline (37 °C, constant temperature) and the time to bleeding cessation was measured. Bleeding time of 15 min was considered as the cut-off time for

the purpose of statistical analysis.

Section 3.3.9. Radioligand Binding Displacement

Resuspended platelets (1×10^9 platelets/ml) were prepared as previously described(115, 129), before they were incubated with 2 nM [^3H]ketanserin at room temperature for 10 min. Next, increasing concentrations of the displacing 5HT_{2A}RAb (10 nM-1 μM) were added for an additional 45 minutes. Next, the [^3H]ketanserin bound platelets were captured by running through 0.45 micron Millipore filters over a vacuum suction unit. The filters were then washed once and counted for radioactivity in a Beckman LS 6000 liquid scintillation counter. To calculate the non-specific binding, the same concentration of radio ligand was competed against 1000-fold excess of unlabeled ketanserin.

Section 3.3.10. Statistical Analysis

All experiments were performed at least three times. Analysis of the data was performed using GraphPad PRISM 7.0 statistical software (San Diego, CA) and presented as mean \pm SD. The Mann-Whitney test was used for the evaluation of differences in mean occlusion and bleeding times. Analysis was also conducted using t-test, and similar results were obtained. Significance was accepted at $P < 0.05$ (two-tailed P value), unless stated otherwise.

Section 3.4. Results

Section 3.4.1. 5HT_{2A}RAb Inhibits Serotonin-enhanced Human Platelet Aggregation

Our initial analysis showed that serotonin (15 μ M) alone does not induce platelet aggregation in human PRP (Fig. 3.1.A). In contrast, we did observe platelet aggregation when stimulating with ADP (1 μ M), albeit it was a “weak” response given the subthreshold dose we used. Concurrent addition/stimulation with serotonin (15 μ M) and ADP (1 μ M) on the other hand resulted in a significant platelet aggregation response (Fig. 3.1.B). These results demonstrate that serotonin by itself cannot induce platelet aggregation, but that it does have the capacity to enhance ADP-induced aggregation. Given that serotonin produces its effects via the 5HT_{2A}R, we investigated if the 5HT_{2A}RAb that targets its ligand-binding site would inhibit serotonin-enhanced ADP-induced platelet aggregation. The data showed that the 5HT_{2A}RAb did inhibit serotonin-enhanced ADP-induced platelet aggregation, dose-dependently (100-150 nM; Fig. 3.1.B), when compared to the vehicle control. We next confirmed that 5HT_{2A}RAb (100 nM) does not affect the platelet activity in the absence of serotonin, and our results revealed that it did not exert any effects on ADP(alone; 10 μ M)-induced aggregation (Fig. 3.1.C). As one would predict, serotonin-induced platelet shape change was inhibited by the 5HT_{2A}RAb (100 nM; (Fig. 3.1.A).




Figure 3.1. The 5HT_{2A}RAb inhibits serotonin-enhanced ADP-induced human platelet aggregation *in vitro*. (A) Human PRP was activated with serotonin (15 μM), with or without pre-incubation for 5 min with 5HT_{2A}RAb (100 nM). (B) Human PRP was preincubated with increasing doses of 5HT_{2A}RAb (100–150 nM) for 5 min before being activated with a combination of ADP (1 μM) and serotonin (15 μM). (C) Human PRP was pre-incubated with 5HT_{2A}RAb (100 nM) for 5 min before activation with ADP (10 mM). Each experiment was repeated at least 3 times, with blood obtained from three separate donors.

Section 3.4.2. 5HT_{2A}RAb Inhibits Serotonin-enhanced Mouse Platelet Aggregation *ex vivo*

We next examined whether the aggregation “antagonistic” activity of the 5HT_{2A}RAb would persist if it was injected into live mice, under multi-dosing conditions. Thus, mice were intravenously injected once daily for 5 days with 5HT_{2A}RAb (100-150 nM). The results revealed that serotonin-induced platelet shape change was inhibited in the 5HT_{2A}RAb (150 nM)-treated mice (Fig. 3.2.A). Moreover, 5HT_{2A}RAb was found to exert inhibitory effects on serotonin-enhanced ADP-induced aggregation in platelets from 5HT_{2A}RAb injected mice, when compared to the vehicle control (Fig. 3.2.B). This finding demonstrates that the inhibitory effects of the 5HT_{2A}RAb are maintained under multi-dosing conditions in live animals.




Figure 3.2. The 5HT_{2A}RAb inhibits serotonin-enhanced ADP-induced mouse platelet aggregation *ex vivo*. (A) Mouse PRP obtained from 5HT_{2A}RAb-injected (150 nM; once daily for 5 days) or control mice was stimulated with serotonin (15 μM). (B) Mouse PRP obtained from either vehicle-injected mice (once daily for 5 days) or 5HT_{2A}RAb-injected mice (100-150 nM; once daily for 5 days) was stimulated with submaximal concentration of ADP (1 μM) in the presence or absence of serotonin (15

μM). Each experiment was repeated at least 3 times, with blood pooled from at least eight mice each time.

Section 3.4.3. The 5HT_{2A}RAb inhibits serotonin-enhanced ADP-induced platelet dense granule secretion in human and mouse platelets *ex vivo*.

Agonist-induced granules release plays a very important role in the amplification of initial platelet activation during primary hemostasis (88-90). Accordingly, we determined if the serotonin antibody exerts any impact on serotonin-enhanced dense granule secretion (ATP). In line with our aggregation data, we observed 5HT_{2A}RAb inhibition of serotonin-enhanced ADP-induced ATP secretion in human platelets (Fig. 3.3.A). This inhibition was also observed under *ex vivo* experimental conditions (Fig. 3.3.B).




Figure 3.3. The 5HT_{2A}RAb inhibits serotonin-enhanced ADP-induced secretion in human and mouse platelets ex vivo. (A) Human PRP was incubated with luciferase luciferin (12.5 μ L) and increasing doses of 5HT_{2A}RAb (100–150 nM) for 5 min before being activated with submaximal concentration of ADP (1 μ M) in the presence or absence of serotonin (15 μ M). (B) Mouse PRP obtained from 5HT_{2A}RAb-injected mice (100-150 nM; once daily for 5 days) was preincubated with luciferase luciferin (12.5 μ L) and stimulated with submaximal concentration of ADP (1 μ M) in the presence or absence of serotonin (15 μ M). ATP release (dense granules) was detected as luminescence and measured by a lumi aggregometer. Each experiment was repeated at least 3 times, with blood pooled from at least eight mice each time.

Section 3.4.4. 5HT_{2A}RAb Inhibits Serotonin-enhanced Platelet α granule Secretion, Glycoprotein IIb/IIIa Activation and Phosphatidylserine Exposure

We next examined whether the 5HT_{2A}RAb exhibits inhibitory effects on separate platelet functional responses that are also known to be enhanced by serotonin, namely α granule secretion (P-selectin expression), GPIIb/IIIa activation and phosphatidylserine (PS) exposure. Thus, human platelets treated with 150 nM 5HT_{2A}RAb before being stimulated with ADP (1 μ M) alone or with a combination of ADP (1 μ M) and serotonin (15 μ M). As expected, the 5HT_{2A}RAb reversed the enhanced P-selectin expression, GPIIb-IIIa activation and PS exposure (Fig. 3.4.A-C), whereas it had no detectable effects on those responses induced by ADP alone. Based on these data, we conclude that 5HT_{2A}RAb inhibits serotonin-enhanced ADP-induced expression of several markers of platelet activation, in addition to aggregation.




Figure 3.4. The 5HT_{2A}RAb Inhibits Serotonin-enhanced ADP-induced α Granule Secretion, GPIIb/IIIa Activation and PS Exposure, in Human Platelets *in vitro*.

Washed platelets were incubated in the presence or absence of the 5HT_{2A}RAb (150 nM) for 5 minutes and then stimulated with ADP (1 μ M), serotonin (15 μ M) or ADP and serotonin (1 μ M and 15 μ M, respectively, for 3 minutes. The reactions were stopped by fixing the platelets with 2% formaldehyde for 30 min at room temperature. (A) Platelets were incubated with FITC-conjugated anti-P-selectin antibody, and the fluorescent intensity was measured by flow cytometry. (B) Platelets were incubated with FITC-conjugated PAC-1 antibody, and the fluorescent intensity was measured by flow cytometry. (C) Platelets were incubated with FITC-conjugated Annexin V antibody, and

the fluorescent intensity was measured by flow cytometry. Each experiment was repeated at least 3 times, with blood obtained from three separate donors.

Section 3.4.5. 5HT_{2A}RAb Prolongs the Thrombus Occlusion Time but not the Tail Bleeding Time

We next sought to assess the prospective of purposing the 5HT_{2A}RAb as an anti-thrombosis agent, *in vivo*. Thus, mice were tail-vein injected with 150 nM of 5HT_{2A}RAb before being subjected to the carotid artery FeCl₃ injury model experiment. Our results showed a significant increase in time to occlusion in the 5HT_{2A}RAb treated mice compared to the vehicle controls (Fig. 3.5.A). We next tested the effects of 5HT_{2A}RAb on hemostasis in order to assess bleeding as a potential adverse effect. We were pleasantly surprised that mice injected with 5HT_{2A}RAb had a bleeding time that was no different from the controls. (Fig. 3.5.B). Together, these results support the notion that 5HT_{2A}RAb protects/delays thrombus formation, and that it does so without increasing the risk of bleeding.




Figure 3.5. 5HT_{2A}RAb prolongs the time to occlusion but not the tail bleeding time, in mice. Mice were injected via the tail vein with 150 nM 5HT_{2A}RAb, once daily for 5 days before being subjected to the FeCl₃ thrombosis and tail bleeding time models. (A) Mean occlusion times for mice treated with 150 nM 5HT_{2A}RAb or vehicle (n = 8). (B) Mean bleeding times for mice treated with 150 nM 5HT_{2A}RAb or vehicle (n = 5). Each point represents the occlusion time or tail bleeding time of a single animal.

Section 3.4.6. 5HT_{2A}RAb Displaces the 5HT_{2A}R Antagonist Ketanserin from its Binding Sites

Finally, while the 5HT_{2A}RAb exerts inhibitory effects on serotonin-enhanced platelet function, this is presumed to involve antagonism of the 5HT_{2A}R. Indeed, increasing concentrations of the 5HT_{2A}RAb (10 nM- 1 μM; inhibition of the Q²¹⁶-N²³³ amino acid region of the receptor's EL2 by 5HT_{2A}RAb) did displace the radiolabeled 5HT_{2A}R antagonist [³H]ketanserin (2 nM) from its binding sites on human platelets (Fig. 3.6.). This effect was reversed by preabsorption of 5HT_{2A}RAb with its cognate peptide (Fig. 3.6.). These data support the notion that 5HT_{2A}RAb's platelet inhibitory effects involve interaction with the 5HT_{2A}R ligand binding domain.




Figure 3.6. 5HT_{2A}RAb displaces the 5HT_{2A}R antagonist from its binding sites. Binding displacement of the radiolabeled 5HT_{2A}R antagonist [³H]ketanserin (2 nM) with increasing concentrations of 5HT_{2A}RAb (10 nM-1 μM) in human platelets; preabsorption of 5HT_{2A}RAb with its cognate peptide (i.e., Q²¹⁶-N²³³) reversed its ability to displace binding of [³H]ketanserin from the 5HT_{2A}R.

Section 3.5. Discussion

According to the National Blood Clot Alliance, it is estimated that 274 people die every day from blood clots. This means one person dies every six minutes due to a blood clot (130-135). While the current FDA approved antiplatelet drugs reduce the risk of recurrent heart attacks, stroke, and death, they are associated with serious side effects (e.g., bleeding) which may outweigh their benefits (136-141). Thus, given the limitations of current thromboembolic therapy (e.g., resistance, and bleeding associated with plavix® and/or aspirin), developing safer drugs continues to be a sought after goal.

It has been demonstrated that serotonin/5HT amplifies aggregation triggered by separate agonists, thereby enhancing thrombogenesis (142, 143). This notion is supported by clinical data demonstrating that increased blood serotonin levels (144) and hyperactive 5-HT_{2A}Rs (144) correlate with cardiac events. Thus, efforts were undertaken to explore the potential beneficial effects of 5HT_{2A}R antagonists as therapy in patients with cardiovascular disease. Unfortunately, while the serotonin 5HT_{2A} receptor (5HT_{2A}R) is known to play a critical role in platelet function *in vivo*, and has been implicated in several forms of cardiovascular disorders, currently there are no FDA-approved 5HT_{2A}R antagonists available for managing thrombotic disease. Nonetheless, a host of such antagonists were designed and examined throughout the years (53-55, 121, 122). For example, the 5HT_{2A}R antagonist ketanserin was shown in clinical studies (121) to reduce the incidence of myocardial infarctions in patients with coronary artery stenosis. However, these results were accompanied by deleterious side-effects due to lack of selectivity for 5HT_{2A}R (121). Subsequent attempts to design antagonists with improved selectivity

profiles produced sarpogrelate, which (initially) showed promise in human clinical studies (122, 145). Unfortunately, this drug did not receive approval by the FDA due to limitations that are likely associated with its activity on 5HT_{2B}R. Later, an experimental 5HT_{2A}R antagonist, namely AR246686 was synthesized and tested for its selectivity and efficacy (55). While AR246686 lacked affinity toward 5HT_{2B}R and 5HT_{2C}R, and exhibited antithrombotic effects *in vitro* and *in vivo*, toxicity has prevented its clinical utility. It is to be noted that the empirical design of these agents and the lack of understanding the 5HT_{2A}R binding domains likely contributed to this failure. Consequently, it has been shown that 5HT_{2A}R ligand binding domain resides in the second extracellular loop (EL2; P²⁰⁹-N²³³) (124-126) which contains amino acid coordination (124, 125, 146-148) sites (S²¹⁹, L²²⁹, A²³⁰, and N²³³), which are either shared or unshared between a number of ligands.

In our efforts to develop a 5HT_{2A}R antagonist, we custom made and characterized an antibody that targets its ligand binding pocket, i.e., the second extracellular loop Q²¹⁶-N²³³ sequence (designated 5HT_{2A}RAb) for its function-blocking activity, in platelets. We demonstrated that this antibody has antiplatelet activities in both human and murine platelet models. Thus, we showed that the 5HT_{2A}RAb inhibited serotonin-enhanced agonist-induced platelet aggregation, whereas it exerted no effects on agonist(alone)-induced aggregation, not only *in vitro* but also *ex vivo* (under multi-dosing conditions). Moreover, the 5HT_{2A}RAb was also found to inhibit the ability of serotonin to enhance agonist-induced secretion, GPIIb/IIIa Activation and PS exposure. Furthermore, we found that the 5HT_{2A}RAb not only protected against thrombosis but that it did so without interfering with physiological hemostasis, in mice. Supportingly, it has been previously

indicated that targeting 5HT_{2A}R allows for the separation of anti-thrombotic activity and bleeding (53-55). Aside from findings that 5HT alone does not stimulate procoagulant responses (149), a likely explanation derives from the belief that the 5HT_{2A}R mediated responses are more involved in the secondary amplification of platelet aggregation in the growing thrombus, rather than playing a primary role in formation and stabilization of a hemostatic thrombus, like ADP and thromboxane A₂. Another explanation is that the antibody cannot penetrate the endothelial cell layer, and hence will not reach the smooth muscle cells; thereby this approach allows for the selective modulation of the platelet 5HT_{2A}R, but not those of the smooth muscle, which are known to affect bleeding time. Together, these data support the notion that the 5HT_{2A}RAb would be superior to classical antagonists because its effects will be limited to the platelet 5HT_{2A}Rs. It is noteworthy that an antibody against the GPIIb/IIIa, known as abciximab/ReoPro[®], has previously been approved by the FDA for antithrombotic purposes. It is possible therefore that 5HT_{2A}RAb would also have clinical use. Notably, radioligand binding studies revealed that the aforementioned 5HT_{2A}RAb inhibitory effects derive from its ability to interact with the 5HT_{2A}R protein.

Section 3.6. Conclusion

In conclusion, our study constitutes the first investigation of function blocking antibody against 5HT_{2A} receptor function. Moreover, it provides novel information concerning a potential target site, i.e. EL2, for therapeutic intervention. Specifically, 5HT_{2A}RAb produces significant effects on platelet function and protects against thrombosis with no effect on bleeding. Collectively, these data suggest that targeting EL2 of 5HT_{2A}R- for

which currently there are no interventions available for clinical use, may define a new class of anti-platelet drugs. Thus, future efforts will focus on generating a monoclonal version of the 5HT_{2A}RAb, and a pharmaceutical formulation for clinical testing.

References

1. World Health Organization. Cardiovascular diseases (CVDs) 2017, May 17 [Available from: [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)#targetText=Key%20facts,31%25%20of%20all%20global%20deaths.](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)#targetText=Key%20facts,31%25%20of%20all%20global%20deaths.)
2. American Heart Association. Heart Disease and Stroke Statistics - At-a-Glance. 2014, December 17.
3. White JG. Platelet morphology: Academic Press, New York; 1971.
4. Weiss HJ. Platelet physiology and abnormalities of platelet function. *New England Journal of Medicine*. 1975;293(11):531-41.
5. Ghoshal K, Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. *The Scientific World Journal*. 2014;2014.
6. Latger-Cannard V, Fenneteau O, Salignac S, Lecompte TP, Schlegel N. Platelet morphology analysis. *Haemostasis*: Springer; 2013. p. 207-25.
7. Andrews RK, Berndt MC. Platelet physiology and thrombosis. *Thrombosis research*. 2004;114(5-6):447-53.
8. Andrews RK, Gardiner EE, Shen Y, Berndt MC. Platelet interactions in thrombosis. *IUBMB life*. 2004;56(1):13-8.
9. Brass LF, Newman DK, Wannemacher K, Zhu L, Stalker TJ. Signal transduction during platelet plug formation. *Platelets*. 2013;2:319-46.
10. Farndale R, Sixma J, Barnes MJ, De Groot PG. The role of collagen in thrombosis and hemostasis. *Journal of Thrombosis and Haemostasis*. 2004;2(4):561-73.
11. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. *Journal of Thrombosis and Haemostasis*. 2003;1(7):1602-12.
12. Kroll MH, Hellums JD, McIntire L, Schafer A, Moake J. Platelets and shear stress. *Blood*. 1996;88(5):1525-41.
13. Rand ML, Israels SJ. Molecular basis of platelet function. *Hematology*. 2018:1870-84. e2.
14. Xiong J-P, Stehle T, Goodman SL, Arnaout MA. New insights into the structural basis of integrin activation. *Blood*. 2003;102(4):1155-9.
15. Chow TW, Hellums JD, Moake JL, Kroll M. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. *Blood*. 1992;80(1):113-20.
16. Saboor M, Ayub Q, Samina Ilyas M. Platelet receptors; an instrumental of platelet physiology. *Pakistan journal of medical sciences*. 2013;29(3):891.
17. Holinstat M. Normal platelet function. *Cancer and Metastasis Reviews*. 2017;36(2):195-8.
18. Clemetson KJ, Clemetson JM. Platelet receptors. *Platelets*: Elsevier; 2019. p. 169-92.
19. Gachet C. ADP receptors of platelets and their inhibition. *Thrombosis and haemostasis*. 2001;86(07):222-32.
20. Orcutt SJ, Krishnaswamy S. Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin. *Journal of Biological Chemistry*. 2004;279(52):54927-36.
21. Hensch NR, Karim ZA, Druey KM, Tansey MG, Khasawneh FT. RGS10 negatively regulates platelet activation and thrombogenesis. *PloS one*. 2016;11(11):e0165984.
22. McCudden C, Hains M, Kimple R, Siderovski D, Willard F. G-protein signaling: back to the future. *Cellular and molecular life sciences*. 2005;62(5):551-77.
23. Dohlman HG. Thematic minireview series: cell biology of G protein signaling. *Journal of Biological Chemistry*. 2015;290(11):6679-80.
24. Offermanns S. Activation of platelet function through G protein-coupled receptors. *Circulation research*. 2006;99(12):1293-304.

25. Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. *Physiological reviews*. 2005;85(4):1159-204.
26. McCorvy JD, Roth BL. Structure and function of serotonin G protein-coupled receptors. *Pharmacology & therapeutics*. 2015;150:129-42.
27. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. *Circulation*. 2014;129(19):1972-86.
28. Qasim H, Karim ZA, Rivera JO, Khasawneh FT, Alshbool FZ. Impact of electronic cigarettes on the cardiovascular system. *Journal of the American Heart Association*. 2017;6(9):e006353.
29. Alexander LEC, Vyas A, Schraufnagel DE, Malhotra A. Electronic cigarettes: the new face of nicotine delivery and addiction. *Journal of thoracic disease*. 2015;7(8):E248.
30. Brandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, et al. Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. *Clinical Cancer Research*. 2015;21(3):514-25.
31. Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. *Scientific reports*. 2014;4:4133.
32. Allem J-P, Dharmapuri L, Unger JB, Cruz TB. Characterizing JUUL-related posts on Twitter. *Drug and alcohol dependence*. 2018;190:1-5.
33. Brett EI, Stevens EM, Wagener TL, Leavens EL, Morgan TL, Cotton WD, et al. A content analysis of JUUL discussions on social media: Using Reddit to understand patterns and perceptions of JUUL use. *Drug and alcohol dependence*. 2019;194:358-62.
34. Kavuluru R, Han S, Hahn EJ. On the popularity of the USB flash drive-shaped electronic cigarette Juul. *Tobacco control*. 2019;28(1):110-2.
35. Keamy-Minor E, McQuoid J, Ling PM. Young adult perceptions of JUUL and other pod electronic cigarette devices in California: a qualitative study. *BMJ open*. 2019;9(4):e026306.
36. Nardone N, Helen GS, Addo N, Meighan S, Benowitz NL. JUUL electronic cigarettes: Nicotine exposure and the user experience. *Drug and alcohol dependence*. 2019.
37. JUUL Labs. What is in JUULpod e-liquid? 2019 [Available from: <https://support.juul.com/hc/en-us/articles/360023364794-What-is-in-JUULpod-e-liquid->].
38. U.S. Food & Drug Administration. WARNING LETTER - JUUL Labs, Inc. 2019, Sep 09 [Available from: <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/juul-labs-inc-590950-09092019>].
39. Jonnakuty C, Gragnoli C. What do we know about serotonin? *Journal of cellular physiology*. 2008;217(2):301-6.
40. Lin OA, Karim ZA, Vemana HP, Espinosa EV, Khasawneh FT. The antidepressant 5-HT_{2A} receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. *PloS one*. 2014;9(1):e87026.
41. Adams JW, Ramirez J, Ortuno D, Shi Y, Thomsen W, Richman JG, et al. Anti-thrombotic and vascular effects of AR246686, a novel 5-HT_{2A} receptor antagonist. *European journal of pharmacology*. 2008;586(1-3):234-43.
42. Bampalis V, Dwivedi S, Shai E, Brandl R, Varon D, Siess W. Effect of 5-HT_{2A} receptor antagonists on human platelet activation in blood exposed to physiologic stimuli and atherosclerotic plaque. *Journal of Thrombosis and Haemostasis*. 2011;9(10):2112-5.
43. Ergelen M, Gorgulu S, Uyarel H, Norgaz T, Aksu H, Ayhan E, et al. The outcome of primary percutaneous coronary intervention for stent thrombosis causing ST-elevation myocardial infarction. *American heart journal*. 2010;159(4):672-6.
44. Dowal L, Flaumenhaft R. Targeting platelet G-protein coupled receptors (GPCRs): looking beyond conventional GPCR antagonism. *Current vascular pharmacology*. 2010;8(2):140-54.

45. Breet N, Sluman M, van Berkel M, Van Werkum J, Bouman H, Harmsze A, et al. Effect of gender difference on platelet reactivity. *Netherlands Heart Journal*. 2011;19(11):451.
46. Bembenek JP, Karlinski M, Kobayashi A, Czlonkowska A. Deep venous thrombosis in acute stroke patients. *Clinical and Applied Thrombosis/Hemostasis*. 2012;18(3):258-64.
47. Moerland M, Kemme M, Dijkmans A, Bergougnan L, Burggraaf J. Modulation of vasoactivity and platelet aggregation by selective 5-HT receptor antagonism in humans. *Journal of cardiovascular pharmacology*. 2011;58(6):575-80.
48. Bonhaus DW, Bach C, DeSouza A, Salazar FR, Matsuoka BD, Zuppan P, et al. The pharmacology and distribution of human 5-hydroxytryptamine_{2B} (5-HT_{2B}) receptor gene products: comparison with 5-HT_{2A} and 5-HT_{2C} receptors. *British journal of pharmacology*. 1995;115(4):622-8.
49. Schins A, Honig A, Crijns H, Baur L, Hamulyák K. Increased coronary events in depressed cardiovascular patients: 5-HT_{2A} receptor as missing link? *Psychosomatic medicine*. 2003;65(5):729-37.
50. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. *Circulation*. 1999;100(5):483-9.
51. Nishihira K, Yamashita A, Tanaka N, Kawamoto R, Imamura T, Yamamoto R, et al. Inhibition of 5-hydroxytryptamine_{2A} receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. *Journal of Thrombosis and Haemostasis*. 2006;4(1):247-55.
52. Pawlak D, Adamkiewicz M, Malyszko J, Takada A, Mysliwiec M, Buczek W. Vascular and cardiac effects of DV-7028, a selective, 5-HT₂-receptor antagonist in rats. *Journal of cardiovascular pharmacology*. 1998;32(2):266-73.
53. Berry CN, Lorrain J, Lochot S, Delahaye M, Lale A, Savi P, et al. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT_{1B}/5-HT_{2A} receptor antagonist. *Thromb Haemost*. 2001;85(3):521-8.
54. Kihara H, Koganei H, Hirose K, Yamamoto H, Yoshimoto R. Antithrombotic activity of AT-1015, a potent 5-HT_{2A} receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. *Eur J Pharmacol*. 2001;433(2-3):157-62.
55. Adams JW, Ramirez J, Ortuno D, Shi Y, Thomsen W, Richman JG, et al. Anti-thrombotic and vascular effects of AR246686, a novel 5-HT_{2A} receptor antagonist. *Eur J Pharmacol*. 2008;586(1-3):234-43.
56. CDC. CDC death report 2014.
57. Qasim H, Karim ZA, Rivera JO, Khasawneh FT, Alshbool FZ. Impact of Electronic Cigarettes on the Cardiovascular System. *J Am Heart Assoc*. 2017;6(9).
58. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. *Chest*. 2007;131(5):1557-66.
59. Centers for Disease Control Prevention. How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease: A report of the surgeon general. 2010.
60. Centers for Disease Control Prevention. Smoking & Tobacco Use 2019, February 6 [Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm#targetText=Smoking%20is%20the%20leading%20cause%20of%20preventable%20death.&targetText=Cigarette%20smoking%20is%20responsible%20for,resulting%20from%20secondhand%20smoke%20exposure].
61. Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. 2018.
62. Wang TW, Gentzke A, Sharapova S, Cullen KA, Ambrose BK, Jamal A. Tobacco product use among middle and high school students—United States, 2011–2017. *Morbidity and Mortality Weekly Report*. 2018;67(22):629.
63. Huang J, Duan Z, Kwok J, Binns S, Vera LE, Kim Y, et al. Vaping versus JUULing: how the extraordinary growth and marketing of JUUL transformed the US retail e-cigarette market. *Tobacco control*. 2019;28(2):146-51.
64. Willett JG, Bennett M, Hair EC, Xiao H, Greenberg MS, Harvey E, et al. Recognition, use and perceptions of JUUL among youth and young adults. *Tob Control*. 2019;28(1):115-6.

65. Fadus MC, Smith TT, Squeglia LM. The rise of e-cigarettes, pod mod devices, and JUUL among youth: Factors influencing use, health implications, and downstream effects. *Drug Alcohol Depend.* 2019;201:85-93.
66. U.S. Food & Drug Administration. Youth Tobacco Use: Results from the National Youth Tobacco Survey 2019, May 29 [Available from: <https://www.fda.gov/tobacco-products/youth-and-tobacco/youth-tobacco-use-results-national-youth-tobacco-survey>].
67. E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General. 2016;2016.
68. CDC CfDCap. YOUTH AND TOBACCO USE. 2015.
69. Leavens ELS, Stevens EM, Brett EI, Hebert ET, Villanti AC, Pearson JL, et al. JUUL electronic cigarette use patterns, other tobacco product use, and reasons for use among ever users: Results from a convenience sample. *Addict Behav.* 2019;95:178-83.
70. Kim AE, Chew R, Wenger M, Cress M, Bukowski T, Farrelly M, et al. Estimated Ages of JUUL Twitter Followers. *JAMA Pediatr.* 2019.
71. Hammond D, Wackowski OA, Reid JL, O'Connor RJ, International Tobacco Control Policy Evaluation Project t. Use of Juul E-Cigarettes Among Youth in the United States. *Nicotine Tob Res.* 2018.
72. Vallone DM, Bennett M, Xiao H, Pitzer L, Hair EC. Prevalence and correlates of JUUL use among a national sample of youth and young adults. *Tob Control.* 2018.
73. FDA. 2018 NYTS Data: A Startling Rise in Youth E-cigarette Use. 2018.
74. U.S. Food & Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on new enforcement actions and a Youth Tobacco Prevention Plan to stop youth use of, and access to, JUUL and other e-cigarettes. 04/24/2018.
75. Qasim H, Karim ZA, Silva-Espinoza JC, Khasawneh FT, Rivera JO, Ellis CC, et al. Short-Term E-Cigarette Exposure Increases the Risk of Thrombogenesis and Enhances Platelet Function in Mice. *Journal of the American Heart Association.* 2018;7(15):e009264.
76. Nocella C, Biondi-Zoccai G, Sciarretta S, Peruzzi M, Pagano F, Loffredo L, et al. Impact of Tobacco Versus Electronic Cigarette Smoking on Platelet Function. *Am J Cardiol.* 2018;122(9):1477-81.
77. Omaiye EE, McWhirter KJ, Luo W, Pankow JF, Talbot P. High-Nicotine Electronic Cigarette Products: Toxicity of JUUL Fluids and Aerosols Correlates Strongly with Nicotine and Some Flavor Chemical Concentrations. *Chem Res Toxicol.* 2019;32(6):1058-69.
78. Vallone DM, Bennett M, Xiao H, Pitzer L, Hair EC. Prevalence and correlates of JUUL use among a national sample of youth and young adults. *Tobacco control.* 2019;28(6):603-9.
79. Goniewicz ML, Boykan R, Messina CR, Eliscu A, Tolentino J. High exposure to nicotine among adolescents who use Juul and other vape pod systems ('pods'). *Tob Control.* 2018.
80. Lee YO, Nonnemaker JM, Bradfield B, Hensel EC, Robinson RJ. Examining Daily Electronic Cigarette Puff Topography Among Established and Non-established Cigarette Smokers in their Natural Environment. *Nicotine Tob Res.* 2017.
81. Robinson RJ, Hensel EC, Roundtree KA, Difrancesco AG, Nonnemaker JM, Lee YO. Week Long Topography Study of Young Adults Using Electronic Cigarettes in Their Natural Environment. *PLoS One.* 2016;11(10):e0164038.
82. Rubenstein D, Jesty J, Bluestein D. Differences between mainstream and sidestream cigarette smoke extracts and nicotine in the activation of platelets under static and flow conditions. *Circulation.* 2004;109(1):78-83.
83. McKelvey K, Baiocchi M, Halpern-Felsher B. Adolescents' and young adults' use and perceptions of pod-based electronic cigarettes. *JAMA network open.* 2018;1(6):e183535-e.
84. Karim ZA, Alshbool FZ, Vemana HP, Adhami N, Dhall S, Espinosa EV, et al. Third-hand smoke: impact on hemostasis and thrombogenesis. *Journal of cardiovascular pharmacology.* 2015;66(2):177-82.

85. Karim ZA, Alshbool FZ, Vemana HP, Conlon C, Druey KM, Khasawneh FT. CXCL12 regulates platelet activation via the regulator of G-protein signaling 16. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*. 2016;1863(2):314-21.
86. de Mendizábal NV, Jones DR, Jahn A, Bies RR, Brown JW. Nicotine and cotinine exposure from electronic cigarettes: a population approach. *Clinical pharmacokinetics*. 2015;54(6):615-26.
87. Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. *Current pharmaceutical design*. 2005;11(17):2199-208.
88. Dawood BB, Wilde J, Watson SP. Reference curves for aggregation and ATP secretion to aid diagnose of platelet-based bleeding disorders: Effect of inhibition of ADP and thromboxane A2 pathways. *Platelets*. 2007;18(5):329-45.
89. Flaumenhaft R, Dilks JR, Rozenvayn N, Monahan-Earley RA, Feng D, Dvorak AM. The actin cytoskeleton differentially regulates platelet α -granule and dense-granule secretion. *Blood*. 2005;105(10):3879-87.
90. Storrie B, Whiteheart SW. Editorial: Platelet Secretion. *Platelets*. 2017;28(2):107.
91. Bennett JS. Structure and function of the platelet integrin α IIb β 3. *The Journal of clinical investigation*. 2005;115(12):3363-9.
92. Joo S-J. Mechanisms of platelet activation and integrin α II β 3. *Korean circulation journal*. 2012;42(5):295-301.
93. Willett JG, Bennett M, Hair EC, Xiao H, Greenberg MS, Harvey E, et al. Recognition, use and perceptions of JUUL among youth and young adults. *Tobacco control*. 2019;28(1):115-6.
94. Krishnan-Sarin S, Jackson A, Morean M, Kong G, Bold KW, Camenga DR, et al. E-cigarette devices used by high-school youth. *Drug and alcohol dependence*. 2019;194:395-400.
95. Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. *American journal of epidemiology*. 2008;169(2):236-48.
96. Raja M, Garg A, Yadav P, Jha K, Handa S. Diagnostic methods for detection of cotinine level in tobacco users: a review. *Journal of clinical and diagnostic research: JCDR*. 2016;10(3):ZE04.
97. McKelvey K, Baiocchi M, Halpern-Felsher B. Adolescents' and Young Adults' Use and Perceptions of Pod-Based Electronic Cigarettes. *JAMA Netw Open*. 2018;1(6):e183535.
98. Goniewicz ML, Boykan R, Messina CR, Eliscu A, Tolentino J. High exposure to nicotine among adolescents who use Juul and other vape pod systems ('pods'). *Tob Control*. 2019;28(6):676-7.
99. Goniewicz ML, Boykan R, Messina CR, Eliscu A, Tolentino J. High exposure to nicotine among adolescents who use Juul and other vape pod systems ('pods'). *Tobacco control*. 2018:tobaccocontrol-2018-054565.
100. Cheng T. Chemical evaluation of electronic cigarettes. *Tobacco control*. 2014;23(suppl 2):ii11-ii7.
101. Sassano MF, Davis ES, Keating JE, Zorn BT, Kochar TK, Wolfgang MC, et al. Evaluation of e-liquid toxicity using an open-source high-throughput screening assay. *PLoS biology*. 2018;16(3):e2003904.
102. Skotsimara G, Antonopoulos AS, Oikonomou E, Siasos G, Ioakeimidis N, Tsalamandris S, et al. Cardiovascular effects of electronic cigarettes: A systematic review and meta-analysis. *Eur J Prev Cardiol*. 2019;26(11):1219-28.
103. Koupenova M, Kehrel BE, Corkrey HA, Freedman JE. Thrombosis and platelets: an update. *Eur Heart J*. 2017;38(11):785-91.
104. Badimon L, Padro T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. *Eur Heart J Acute Cardiovasc Care*. 2012;1(1):60-74.
105. Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. *Blood reviews*. 2011;25(4):155-67.
106. McMichael M. Primary hemostasis. *Journal of veterinary emergency and critical care*. 2005;15(1):1-8.

107. Nieuwenhuis HK, Sakariassen KS, Houdijk WP, Nievelstein PF, Sixma JJ. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. *Blood*. 1986;68(3):692-5.
108. Staatz WD, Walsh JJ, Pexton T, Santoro SA. The alpha 2 beta 1 integrin cell surface collagen receptor binds to the alpha 1 (I)-CB3 peptide of collagen. *J Biol Chem*. 1990;265(9):4778-81.
109. Charo IF, Feinman RD, Detwiler TC. Interrelations of platelet aggregation and secretion. *J Clin Invest*. 1977;60(4):866-73.
110. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. *Nature*. 1962;194:927-9.
111. Parise LV, Venton DL, Le Breton GC. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. *J Pharmacol Exp Ther*. 1984;228(1):240-4.
112. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. *Proc Natl Acad Sci U S A*. 1975;72(8):2994-8.
113. Ghali NI, Kattelman EJ, Hung SC, Schnorf KE, Le Breton GC, Venton DL. Synthesis of [17,18-3H] trans-13-azaprostanoic acid. A labeled probe for the PGH2/TXA2 receptor. *Prostaglandins*. 1984;27(6):865-76.
114. Halushka PV, Mais DE, Mayeux PR, Morinelli TA. Thromboxane, prostaglandin and leukotriene receptors. *Annu Rev Pharmacol Toxicol*. 1989;29:213-39.
115. Hung SC, Ghali NI, Venton DL, Le Breton GC. Specific binding of the thromboxane A2 antagonist 13-azaprostanoic acid to human platelet membranes. *Biochim Biophys Acta*. 1983;728(2):171-8.
116. Woulfe DS. Platelet G protein-coupled receptors in hemostasis and thrombosis. *J Thromb Haemost*. 2005;3(10):2193-200.
117. Collier BS. Platelets and thrombolytic therapy. *N Engl J Med*. 1990;322(1):33-42.
118. Weiss HJ. Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis. *Am Heart J*. 1976;92(1):86-102.
119. Kagaya A, Mikuni M, Yamamoto H, Muraoka S, Yamawaki S, Takahashi K. Heterologous supersensitization between serotonin2 and alpha 2-adrenergic receptor-mediated intracellular calcium mobilization in human platelets. *J Neural Transm Gen Sect*. 1992;88(1):25-36.
120. Offermanns S. Activation of platelet function through G protein-coupled receptors. *Circ Res*. 2006;99(12):1293-304.
121. Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. *BMJ*. 1989;298(6671):424-30.
122. Tanaka T, Fujita M, Nakae I, Tamaki S, Hasegawa K, Kihara Y, et al. Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. *J Am Coll Cardiol*. 1998;32(7):1982-6.
123. Noble MI, Ford I, Cameron G, Drake-Holland A. The Novel Anti-Thrombotic Drug with No-Bleeding Excess. *J Cardiol Cardiovasc Therap*. 2017.
124. Cordova-Sintjago T, Sakhuja R, Kondabolu K, Canal CE, Booth RG. Molecular Determinants for Ligand Binding at Serotonin 5-HT2A and 5-HT2C GPCRs: Experimental Affinity Results Analyzed by Molecular Modeling and Ligand Docking Studies. *Int J Quantum Chem*. 2012;112(24):3807-14.
125. Nichols DE, Nichols CD. Serotonin receptors. *Chem Rev*. 2008;108(5):1614-41.
126. Westkaemper RB, Glennon RA. Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands. *Curr Top Med Chem*. 2002;2(6):575-98.
127. Hensch NR, Karim ZA, Pineda J, Mercado N, Alshbool FZ, Khasawneh FT. P2Y12 antibody inhibits platelet activity and protects against thrombogenesis. *Biochemical and biophysical research communications*. 2017;493(2):1069-74.

128. Karim ZA, Alshbool FZ, Vemana HP, Adhami N, Dhall S, Espinosa EV, et al. Third-hand Smoke: Impact on Hemostasis and Thrombogenesis. *J Cardiovasc Pharmacol*. 2015;66(2):177-82.
129. Kattelman EJ, Venton DL, Le Breton GC. Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA₂/PGH₂ receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). *Thromb Res*. 1986;41(4):471-81.
130. Yusuf HR, Reyes N, Zhang QC, Okoroh EM, Siddiqi A-E-A, Tsai J. Hospitalizations of adults ≥ 60 years of age with venous thromboembolism. *Clinical and Applied Thrombosis/Hemostasis*. 2014;20(2):136-42.
131. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. *Bmj*. 2011;342:d3036.
132. Kearon C. Natural history of venous thromboembolism. *Circulation*. 2003;107(23_suppl_1):I-22-I-30.
133. Heit JA. The epidemiology of venous thromboembolism in the community. *Arteriosclerosis, thrombosis, and vascular biology*. 2008;28(3):370-2.
134. Heit JA, Cohen AT, Anderson FA. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. *Am Soc Hematology*; 2005.
135. National Blood Clot Alliance. BLOOD CLOTS IN THE UNITED STATES Reviewed at 08/07/2019 [Available from: <https://www.stoptheclot.org/blood-clot-information/blood-clots-in-the-united-states/>].
136. Trialists' Collaboration A. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *Bmj*. 2002;324(7329):71-86.
137. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Elsevier*; 2009.
138. Hankey G, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. *Cochrane Database of systematic reviews*. 2000(1).
139. Kim H-H, Liao JK. Translational therapeutics of dipyridamole. *Arteriosclerosis, thrombosis, and vascular biology*. 2008;28(3):s39-s42.
140. Chakrabarti S, Freedman JE. Dipyridamole, cerebrovascular disease, and the vasculature. *Vascular pharmacology*. 2008;48(4-6):143-9.
141. Vestergaard P, Steinberg TH, Schwarz P, Jørgensen NR. Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture. *International journal of cardiology*. 2012;160(1):36-40.
142. De Clerck FF, Herman AG. 5-hydroxytryptamine and platelet aggregation. *Fed Proc*. 1983;42(2):228-32.
143. De Clerck FF, Janssen PA. Amplification mechanisms in platelet activation and arterial thrombosis. *J Hypertens Suppl*. 1990;8(7):S87-93.
144. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. *Circulation*. 1999;100(5):483-9.
145. Fujita M, Mizuno K, Ho M, Tsukahara R, Miyamoto A, Miki O, et al. Sarpogrelate treatment reduces restenosis after coronary stenting. *Am Heart J*. 2003;145(3):E16.
146. Almaula N, Ebersole BJ, Zhang D, Weinstein H, Sealfon SC. Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine_{2A} receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. *J Biol Chem*. 1996;271(25):14672-5.

147. Shan J, Khelashvili G, Mondal S, Mehler EL, Weinstein H. Ligand-dependent conformations and dynamics of the serotonin 5-HT(2A) receptor determine its activation and membrane-driven oligomerization properties. *PLoS Comput Biol.* 2012;8(4):e1002473.
148. Wang CD, Gallaher TK, Shih JC. Site-directed mutagenesis of the serotonin 5-hydroxytryptamine₂ receptor: identification of amino acids necessary for ligand binding and receptor activation. *Mol Pharmacol.* 1993;43(6):931-40.
149. Li N, Wallen NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. *Blood Coagul Fibrinolysis.* 1997;8(8):517-23.

Vita

Jean E. Montes started his college education at The University of Texas at El Paso (UTEP). Mr. Montes obtained a Bachelor's degree in Biochemical Engineering in the Fall of 2017. In the Spring of 2018, he was admitted into the Biomedical Engineering Master's program and joined Dr. Fatima Alshbool's laboratory in the Department of Pharmaceutical Sciences, School of Pharmacy at UTEP. Besides his graduate education, Mr. Montes also worked as a teaching assistant in the School of Pharmacy. During his career, he studied cardiovascular disease, specifically, that which is thrombosis-based via modulation of platelet function.

Mr. Montes' research projects focused on studying the health safety profile of JUUL, a popular electronic cigarette (e-cigarettes) in the U.S. Moreover, Mr. Montes' findings confirm that a novel antibody targeting the serotonin-receptor 5HT_{2A}R ligand binding domain could be used as an antithrombotic agent. Mr. Montes continues to expand his knowledge about cardiovascular diseases and thrombosis to improve health public awareness and help to develop novel antiplatelet agents for therapeutic use.

Mr. Montes will continue in the biomedical research field and will begin a doctorate degree in the spring of 2020.

Contact Information: jemontesramirez@miners.utep.edu